Bromobenzene

Bromobenzene

SCHEMBL313507

Brc1ccccc1.F.F.F

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.92
TDP1 Q9NUW8 1/20 0.92
MAPK1 P28482 4/20 0.59
CYP2A6 P11509 2/20 0.54
HTR2A P28223 1/20 0.42
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
G6PD P11413 1/20 0.37
AKR1C3 P42330 1/20 0.37
MEN1 O00255 1/20 0.37
CASP3 P42574 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromobenzene SCHEMBL29116318 1.00 ALDH1A1 (0.92) ALDH1A1TDP1MAPK1CYP2A6HTR2A
Bromobenzene SCHEMBL27532658 1.00
Bromobenzene SCHEMBL27338894 1.00
Bromobenzene SCHEMBL28159228 1.00 ALDH1A1 (0.92) ALDH1A1TDP1MAPK1CYP2A6HTR2A
Bromobenzene SCHEMBL1736835 1.00 ALDH1A1 (0.92) ALDH1A1TDP1MAPK1CYP2A6HTR2A
Bromobenzene SCHEMBL313505 1.00 ALDH1A1 (0.92) ALDH1A1TDP1MAPK1CYP2A6HTR2A
Bromobenzene SCHEMBL1736832 1.00 ALDH1A1 (0.92) ALDH1A1TDP1MAPK1CYP2A6HTR2A
Bromobenzene SCHEMBL6274950 0.96 ALDH1A1 (0.85) ALDH1A1TDP1MAPK1CYP2A6HTR2A
Bromobenzene SCHEMBL537562 0.96 ALDH1A1 (1.00) ALDH1A1TDP1MAPK1CYP2A6HTR2A
Bromobenzene SCHEMBL1331176 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12406696-B2 Photopolymer compositions for thermostable photopolymers in the visible spectral range COVESTRO DEUTSCHLAND AG (DE) 2025-09-02 US disclosed
US-20250182787-A1 Photopolymer Compositions for Thermostable Photopolymers in the Visible Spectral Range COVESTRO DEUTSCHLAND AG (DE) 2025-06-05 US disclosed
US-20250171648-A1 Thermostable Photopolymers in the Visible Spectral Range and Photopolymer Compositions Containing Same COVESTRO DEUTSCHLAND AG (DE) 2025-05-29 US disclosed
US-20250155845-A1 Triarylalkyl Borate Salts as Coinitiators in NIR Photopolymer Compositions COVESTRO DEUTSCHLAND AG (DE) 2025-05-15 US disclosed
CN-118742960-A Photopolymer composition of thermally stable photopolymer in the visible spectral range 科思创德国股份有限公司 2024-10-01 CN disclosed
CN-118742958-A Triarylalkyl borates as co-initiators in NIR photopolymer compositions 科思创德国股份有限公司 2024-10-01 CN disclosed
CN-118742959-A Thermally stable photopolymers in the visible spectrum and photopolymer compositions comprising same 科思创德国股份有限公司 2024-10-01 CN disclosed
WO-2023156485-A1 TRIARYLALKYL BORATE SALTS AS COINITIATORS IN NIR PHOTOPOLYMER COMPOSITIONS COVESTRO DEUTSCHLAND AG (DE) 2023-08-24 WO disclosed
WO-2023156484-A1 PHOTOPOLYMER COMPOSITIONS FOR THERMOSTABLE PHOTOPOLYMERS IN THE VISIBLE SPECTRAL RANGE COVESTRO DEUTSCHLAND AG (DE) 2023-08-24 WO disclosed
WO-2023156482-A1 THERMOSTABLE PHOTOPOLYMERS IN THE VISIBLE SPECTRAL RANGE AND PHOTOPOLYMER COMPOSITIONS CONTAINING SAME COVESTRO DEUTSCHLAND AG (DE) 2023-08-24 WO disclosed
WO-2005058885-A2 PIPERIDINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-30 WO disclosed
US-20050043544-A1 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-24 US disclosed
US-20050038296-A1 Organic electrolumescence device IDEMITSU KOSAN CO., LTD. (JP) 2005-02-17 US disclosed
EP-1471056-A1 PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME Takeda Chemical Industries, Ltd. (JP) 2004-10-27 EP disclosed
US-6743948-B1 HAVING DUAL CHRYSENE RINGS LINKED BY AMINO FUNCTIONALITY HAVING FURTHER ARYL AND ALKENYL SUBSTITUTION; EFFICIENCY; HEAT RESISTANCE; DURABILITY IDEMITSU KOSAN CO., LTD. (JP) 2004-06-01 US disclosed
US-20040033935-A1 Novel imidazole derivatives, production method thereof and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-19 US disclosed
EP-1334106-A2 NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-08-13 EP disclosed
WO-2002040484-A2 NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-05-23 WO disclosed
EP-1061112-A1 ORGANIC ELECTROLUMINESCENT ELEMENT IDEMITSU KOSAN COMPANY LIMITED (JP) 2000-12-20 EP disclosed
US-4593047-A Alcoholism RICHTER GEDEON VEGYESZETI CYAR RT (HU) 1986-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033935-A1 Novel imidazole derivatives, production method thereof and use thereof CYP17A1, CYP21A2, CYP19A1 ALDH1A1 227/4885TDP1 2019/4885MAPK1 2678/4885
US-20050043544-A1 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same CYP17A1, HSD17B7, HSD17B1 ALDH1A1 1246/4885TDP1 4649/4885MAPK1 4015/4885
US-20050038296-A1 Organic electrolumescence device CHRM1, SCO2, CHRM4 ALDH1A1 1747/4885TDP1 2609/4885MAPK1 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.